Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson’s disease
MainParkinson’s disease (PD) is characterized by the loss of dopamine (DA) neurons in the substantia nigra, leading to a motor syndrome characterized by bradykinesia, rigidity and resting tremor. Medical treatment effectively alleviates PD symptoms in the early stages, but chronic use results in complications such as motor fluctuations and drug-induced dyskinesias. Consequently, cell therapies to replace lost DA neurons have been investigated as an alternative treatment.Initial open-label studie...
Read more at nature.com